Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05154240




Registration number
NCT05154240
Ethics application status
Date submitted
17/11/2021
Date registered
13/12/2021
Date last updated
29/06/2023

Titles & IDs
Public title
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
Scientific title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Oral Single and Multiple Ascending Doses, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
Secondary ID [1] 0 0
INS018-055-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - INS018_055
Treatment: Drugs - Placebo

Active Comparator: INS018_055 - oral doses of INS018_055_single dose; oral doses of INS018_055_multiple ascending dose over 10days.

Placebo Comparator: Placebo - No active ingredient. Frequency similar to the 2 arms above.


Treatment: Drugs: INS018_055
INS018_055 is a small molecule compound. INS018_055 has good solubility in water and was chemically and physically stable at different temperatures.

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with treatment-related adverse events based on subjective and objective examination
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Maximum Plasma Concentration [Cmax]
Timepoint [1] 0 0
12 months
Secondary outcome [2] 0 0
Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)
Timepoint [2] 0 0
12 months
Secondary outcome [3] 0 0
AUC from time 0 extrapolated to infinity (AUC0-inf)
Timepoint [3] 0 0
12 months
Secondary outcome [4] 0 0
AUC from time 0 to the time of the dosing interval (To; AUC0-To)
Timepoint [4] 0 0
12 months
Secondary outcome [5] 0 0
Accumulation ratio (AR), calculated as AUC0-To (Day 10)/AUC0-To (Day 1)
Timepoint [5] 0 0
12 months
Secondary outcome [6] 0 0
AR calculated as Cmax (Day 10)/Cmax (Day 1)
Timepoint [6] 0 0
12 months
Secondary outcome [7] 0 0
Time to reach Cmax (Tmax)
Timepoint [7] 0 0
12 months
Secondary outcome [8] 0 0
Pre-dose concentrations on Days 1 through 10 (C trough)
Timepoint [8] 0 0
12 months
Secondary outcome [9] 0 0
Average concentration on Day 1 and Day 10 (Cav)
Timepoint [9] 0 0
12 months
Secondary outcome [10] 0 0
Terminal elimination rate constant (Kel)
Timepoint [10] 0 0
12 months
Secondary outcome [11] 0 0
Terminal elimination half-life (t1/2)
Timepoint [11] 0 0
12 months
Secondary outcome [12] 0 0
Apparent total body clearance (CL/F)
Timepoint [12] 0 0
12 months
Secondary outcome [13] 0 0
Peak to trough ratio calculated as Cmax/Ctrough
Timepoint [13] 0 0
12 months
Secondary outcome [14] 0 0
Apparent volume of distribution (Vd/F)
Timepoint [14] 0 0
12 months
Secondary outcome [15] 0 0
Metabolite-to parent ratio based on AUC calculated as AUCmetabolite/AUCparent
Timepoint [15] 0 0
12 months
Secondary outcome [16] 0 0
Metabolite-to parent ratio based on Cmax calculated as Cmax, metabolite/Cmax, parent
Timepoint [16] 0 0
12 months
Secondary outcome [17] 0 0
Renal clearance (CLr)
Timepoint [17] 0 0
12 months
Secondary outcome [18] 0 0
Total amount of drug excreted unchanged in urine from 0 to 24 hours after dosing (XU0-24)
Timepoint [18] 0 0
12 months

Eligibility
Key inclusion criteria
1. The subject is a male or female 18 to 55 years of age, inclusive.

2. The subject has a body mass index 18 to 32 kg/m2, inclusive, and a total body weight
=50 kg, inclusive, at screening.

3. The subject is considered by the investigator to be in good general health as
determined by medical history, clinical laboratory test results, vital sign
measurements, 12-lead ECG results, and physical examination findings at screening.

4. Female subjects of childbearing potential must be non-pregnant and non-lactating and
must use one of the methods of contraception listed below for the duration of the
treatment until at least 28 days after the last dose of the study drug, or be
surgically sterile (ie, hysterectomy, bilateral tubal ligation, or bilateral
oophorectomy), or postmenopausal (defined as amenorrhea 12 consecutive months and
documented plasma follicle stimulating hormone level >40 IU/mL). Female subjects must
have a negative pregnancy test at screening and before the first dose of study drug.

Highly effective methods of contraception are those that result in a failure rate of
less than 1% per year when used consistently. Examples are provided below:

1. Implant contraceptive (eg, Jadelle®)

2. Intrauterine device containing either copper or levonorgestrel (eg, Mirena®)

3. Male sterilization with absence of sperm in the post-vasectomy ejaculate

OR an effective method that result in a failure rate of less than 5% to 10% per
year. Examples are provided below:

4. Injectable contraceptive (eg, Depo Provera)

5. Oral contraceptive pill (combined hormonal contraceptive pill or progestogen-only
'mini-pill')

6. Vaginal contraceptive ring (eg, NuvaRing®)

Female subjects must also agree not to donate eggs, from dosing until at least 28 days
after the last dose of study drug.

A male subject and his female partner who is of childbearing potential must agree to
use one of the methods of contraception listed above for the duration of the treatment
until at least 28 days after the last dose of the study drug. A male subject must also
agree not to donate sperm, for the duration of the treatment until at least 28 days
after the last dose of the study drug.

5. The subject agrees to comply with all protocol requirements.

6. The subject is able to provide written informed consent.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. The subject has current evidence or history of clinically significant hematological,
renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
neurologic, or allergic disease (including drug allergies, but excluding untreated,
asymptomatic, seasonal allergies at time of dosing).

2. The subject has any condition possibly affecting drug absorption (eg, gastrectomy).

3. The subject has a history of cancer with the exception of adequately treated basal
cell or squamous cell carcinoma of the skin.

4. The subject has supine blood pressure (BP) >140 mm Hg (systolic) or >90 mm Hg
(diastolic), following at least 5 minutes of supine rest. If BP is >140 mm Hg
(systolic) or >90 mm Hg (diastolic), the BP should be repeated 2 more times and the
average of the 3 BP values should be used to determine the subject's eligibility at
screening.

5. The subject has 12-lead ECG demonstrating corrected QT interval by Fridericia (QTcF)
>450 msec, or a QRS interval >120 msec at screening. If QTcF exceeds 450 msec, or QRS
interval exceeds 120 msec, the ECG should be repeated 2 more times and the average of
the 3 QTcF (or QRS interval) values should be used to determine the subject's
eligibility.

6. The subject has ANY of the following abnormalities in clinical laboratory tests at
screening, as assessed by the study-specific laboratory and confirmed by a single
repeat, if deemed necessary:

1. Serum creatinine level above the upper limit of normal (ULN) or an estimated
glomerular filtration rate value <80 mL/min/1.73 m2 calculated with the Chronic
Kidney Disease Epidemiology Collaboration formula and the absence of protein in
urine, at screening.

2. Aspartate aminotransferase or alanine aminotransferase values more than >1.5 ×
ULN.

3. Fasting glucose >110 mg/dL (6.1 mmol/L).

4. Total bilirubin >1.5 × ULN.

5. Hematological values outside the normal reference range for local laboratory
results.

6. Positive fecal occult blood test at screening or at check-in (Day -1).

7. The subject has any medical history of disease that has the potential to cause a rise
in total bilirubin over the ULN. Subjects with borderline clinical laboratory values
outside the reference range may be included in the study if the investigator deems
that the values are not clinically significant.

Note: Subjects with a history of Gilbert's syndrome may have a direct bilirubin
measured and would be eligible for this study provided the direct bilirubin is <ULN.

8. The subject has a history of any lymphoproliferative disorder (such as Epstein Barr
Virus related lymphoproliferative disorder, as reported in some subjects on
immunosuppressive drugs), history of lymphoma, leukemia, myeloproliferative disorders,
multiple myeloma, or signs and symptoms suggestive of current lymphatic disease.

9. The subject has a history of relevant drug and/or food allergies (ie, allergy to any
study drug or excipients, or any significant food allergy that could preclude a
standard diet in the clinical unit).

10. The subject has a clinically significant infection currently or within 6 months of
first dose of study drug (eg, those requiring hospitalization or parenteral
antimicrobial therapy or opportunistic infections within the last 6 months), or a
history of chronic or recurrent infectious disease.

11. The subject has other severe acute or chronic medical or psychiatric condition
including recent (within the past year) or active suicidal ideation or behavior or
laboratory abnormality that may increase the risk associated with study participation
or investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.

12. The subject has or has had symptomatic herpes zoster or herpes simplex within 12
weeks, more than one episode of local herpes zoster, or a history (single episode) of
disseminated zoster.

13. The subject has a positive test result for hepatitis B surface antigen, hepatitis C
virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening.

14. The subject is a female who is pregnant or lactating.

15. The subject is a fertile male who is unwilling or unable to use a highly effective
method of contraception as outlined in this protocol for the duration of the study and
for at least 28 days after the last dose of investigational product.

16. The subject is unwilling or unable to comply with the lifestyle restrictions described
in this protocol.

17. The subject is a smoker or has used nicotine or nicotine-containing products (eg,
snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6
months before the first dose of study drug.

18. The subject has a positive test result for drugs of abuse, or cotinine (indicating
active current smoking) at screening or before the first dose of study drug.

19. The subject has used any prescription or over the counter medications (except
paracetamol [up to 2 g per day]), including herbal supplements, within 14 days before
the first dose of study drug. Nutritional supplements are allowed if unlikely to
interfere with the study results and agreed by medical monitor and investigator.

20. The subject has consumed grapefruit or grapefruit juice, Seville orange or Seville
orange containing products (eg, marmalade), or alcohol-, caffeine-, or xanthine
containing products within 48 hours before the first dose of study drug.

21. The subject will have vaccination with live virus, attenuated live virus, or any live
viral components within 2 weeks prior to the first dose of study drug or is to receive
these vaccines at any time during treatment or within 8 weeks following completion of
study treatment.

22. The subject has a positive test result for severe acute respiratory syndrome-related
coronavirus 2 (SARS-CoV-2). The subject has received the Coronavirus disease 2019
(COVID-19) vaccine within 2 weeks prior to the first dose of study drug or plans to
receive a COVID-19 vaccine within 12 weeks after study drug dosing or has positive
test for SARS CoV 2 during screening or presence of COVID 19 symptoms within 4 weeks
prior to Day -1.

23. The subject has undergone significant trauma or major surgery within 4 weeks of
screening.

24. The subject has bleeding risk: genetic predisposition to bleeding, a hemorrhagic event
in the 12 months before the start of screening, or abnormal laboratory coagulation
parameters.

25. The subject has a first-degree relative with a hereditary immunodeficiency.

26. The subject has investigator site staff members directly involved in the conduct of
the study and their family members, site staff members otherwise supervised by the
investigator, or subjects who are sponsor employees including their family members are
directly involved in the conduct of the study.

27. The subject has a history of alcohol abuse or drug addiction within the last year or
excessive alcohol consumption (regular alcohol intake >21 units per week for male
subjects and >14 units of alcohol per week for female subjects) (1 unit is equal to
approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure
[25 mL] of spirits) or use of alcohol 48 hours before the first dose of study drug.

28. The subject is involved in strenuous activity or contact sports within 24 hours before
dosing and during the study.

29. The subject has donated blood or blood products >450 mL within 30 days before the
first dose of study drug.

30. The subject has received study drug in another investigational study within 30 days of
dosing.

31. The subject received cytochrome P450 (CYP)/ multidrug and toxin extrusion (MATE)
classes of medications within 4 weeks of first dose of INS018_055 or was likely to
receive CYP/MATE classes of medications during the study.

32. In the opinion of the investigator, the subject is not suitable for entry into the
study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
2/12/2022
Sample size
Target
Accrual to date
Final
78
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
InSilico Medicine Hong Kong Limited
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled,
oral single and multiple ascending-doses, parallel group study to evaluate the safety,
tolerability and PK of INS018_055 in healthy subjects. The study will be conducted in 1
clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose [SAD])
and Part B (multiple ascending dose [MAD]).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05154240
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Christopher J Wynne, MBChB
Address 0 0
New Zealand Clinical Research
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries